Menu Search
Equities

Adaptive Biotechnologies Corp

1HM:FRA

Adaptive Biotechnologies Corp

Actions
  • Price (EUR)5.49
  • Today's Change-0.514 / -8.56%
  • Shares traded984.00
  • 1 Year change+70.12%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Adaptive Biotechnologies Corp's revenues fell -8.11% from 185.31m to 170.28m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 200.19m to a larger loss of 225.25m.
Gross margin58.46%
Net profit margin-110.19%
Operating margin-112.69%
Return on assets-30.61%
Return on equity-66.69%
Return on investment-35.66%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Adaptive Biotechnologies Corp fell by 24.43m. However, Cash Flow from Investing totalled 129.65m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 156.32m for operations while cash generated from financing totalled 2.25m.
Cash flow per share-1.20
Price/Cash flow per share--
Book value per share1.52
Tangible book value per share0.6841
More ▼

Balance sheet in USDView more

Adaptive Biotechnologies Corp has a Debt to Total Capital ratio of 37.25%, a higher figure than the previous year's 35.03%.
Current ratio3.52
Quick ratio3.38
Total debt/total equity0.593
Total debt/total capital0.3725
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.